Kenvue Inc. $KVUE Shares Purchased by Moors & Cabot Inc.

Moors & Cabot Inc. raised its position in Kenvue Inc. (NYSE:KVUE) by 66.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 313,122 shares of the company’s stock after purchasing an additional 125,517 shares during the quarter. Moors & Cabot Inc.’s holdings in Kenvue were worth $5,082,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in KVUE. AlphaCore Capital LLC grew its stake in shares of Kenvue by 9.9% in the second quarter. AlphaCore Capital LLC now owns 5,287 shares of the company’s stock valued at $111,000 after buying an additional 476 shares in the last quarter. Empirical Finance LLC boosted its holdings in Kenvue by 1.8% during the 2nd quarter. Empirical Finance LLC now owns 28,309 shares of the company’s stock valued at $593,000 after acquiring an additional 491 shares during the period. J.W. Cole Advisors Inc. grew its position in Kenvue by 3.8% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 15,488 shares of the company’s stock valued at $324,000 after acquiring an additional 574 shares in the last quarter. Versor Investments LP increased its stake in Kenvue by 2.8% during the third quarter. Versor Investments LP now owns 26,016 shares of the company’s stock worth $422,000 after purchasing an additional 716 shares during the period. Finally, Patton Fund Management Inc. lifted its position in shares of Kenvue by 8.1% during the third quarter. Patton Fund Management Inc. now owns 10,353 shares of the company’s stock worth $168,000 after purchasing an additional 780 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Up 1.3%

KVUE opened at $17.72 on Tuesday. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17. The company has a market cap of $33.95 billion, a P/E ratio of 23.01, a PEG ratio of 3.97 and a beta of 0.51. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.96. The business’s 50-day simple moving average is $17.91 and its 200-day simple moving average is $17.26.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.05. The firm had revenue of $3.78 billion during the quarter, compared to analysts’ expectations of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The firm’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.26 earnings per share. As a group, equities research analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th were given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.7%. The ex-dividend date was Wednesday, February 11th. Kenvue’s payout ratio is currently 107.79%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on KVUE. Zacks Research raised shares of Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Barclays raised their price target on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Friday, March 6th. Jefferies Financial Group downgraded shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the stock from $23.00 to $18.00 in a research note on Friday, January 30th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. Finally, UBS Group lifted their target price on Kenvue from $17.00 to $19.00 and gave the company a “neutral” rating in a report on Wednesday, February 18th. Three investment analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to data from MarketBeat, Kenvue has a consensus rating of “Hold” and an average target price of $19.58.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.